Geron (NASDAQ:GERN) Earns Outperform Rating from Wedbush

Wedbush restated their outperform rating on shares of Geron (NASDAQ:GERN – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $6.00 price objective on the biopharmaceutical company’s stock. Separately, Needham & Company LLC reissued a buy rating and set a $4.00 price target on shares of […]

Related Keywords

United States ,American , ,Needham Company ,Geron Company Profile ,Nisa Investment Advisors ,Geron Corporation ,Financial Services Group Inc ,Cerity Partners ,Asset Management Inc ,Free Report ,Get Free Report ,Investment Advisors ,Management Inc ,Services Group ,Geron Daily ,Orgeron ,Nasdaq Gern ,Egern ,Medical ,37416310 ,Reiterated Rating ,Wedbush ,